Dudediligence.

Gain Therapeutics, Inc

GANXNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

43.3M

on 2026-06-30, from 18.0M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

10M20M30M40MMar2024JunSepDecMar2025JunSep$1.555DecMar2026Jun

Newest

S-3 of 2025-05-28. Not read yet. S-3 ↗

$50.0M

Oppenheimer, agreement of 2025-11-28. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

5.27M

Warrants of every class as tagged in the XBRL facts on 2026-06-30. 10-Q ↗

Cash

2.8 quarters

$13.1M on 2026-06-30 ÷ $4.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-07-16Public offering with warrants at $1.654,501,640$1.555$7.0M424B5 ↗